Her parents say she danced her way through leukemia. On Friday night, a 4-year-old girl’s wish to dance with real ballerinas was granted. Charlotte Grimm, who is from Minnesota, got a chance to dance with real ballerinas at the Civic Theatre in downtown San Diego. In February of 2010, Charlotte was diagnosed with acute lymphoblastic leukemia. “She had had a couple unexplained high fevers and we took her into the pediatrician thinking she was just
(More)…
SAVANNAH, GA (WTOC) – The Savannah chapter of the Leukemia and Lymphoma Society is holding a benefit concert Friday night to raise funds in honor of a couple of young people who have battled blood cancers. The Country for a Cure concert will begin at 7:30 p.m. at Tubby’s in Thunderbolt. There will be live performers on the porch and more inside. The bands say they are going to play until they shut them down.
(More)…
Trey Roy’s family was devastated when he was diagnosed with leukemia in July 2011. The little boy from St. Albans has maintained a positive attitude throughout his ordeal and has inspired others with his charismatic personality. The last time Trey Roy appeared on 13 News he was on the sidelines at the football field at Hayes Middle School watching his friends with the Tornado Tigers on the field, wishing he could play. But nine months
(More)…
ALBANY, N.Y., May 16 (UPI) — A 26-year-old U.S. woman diagnosed with chronic myelogenous leukemia in 2010 says she might not be alive if not for $200,000 in free cancer medication. Alysia Santo, a 2011 alumna of Columbia University’s Graduate School of Journalism, is currently working for the Albany (N.Y.) Times Union Investigations Team via a Hearst Corp. Office of General Counsel fellowship. “I was working as a waitress and uninsured at the time (of
(More)…
By Bill Berkrot (Reuters) – An experimental leukemia treatment that Roche Holding AG hopes will improve upon its best-selling cancer drug Rituxan delayed disease progression twice as long as chemotherapy, according to preliminary trial data released on Wednesday. Switzerland-based Roche aims to fend off cheaper competition for Rituxan, which loses patent protection in Europe later this year, threatening a product with nearly $7 billion in annual sales. Roche’s new drug in development, known as GA101
(More)…
Darren Hauck for The New York Times On the shores of Lake Michigan. When people choose to have their leukemia treated aggressively, it’s a big commitment, more so than for almost any other cancer. With this therapy — three days of the drug daunorubicin, which comes in a reddish color so distinctive that one of my patients, a former chemist, used it in his professional life as a dye for plastics, and seven days of
(More)…
Darren Hauck for The New York Times On the shores of Lake Michigan. When people choose to have their leukemia treated aggressively, it’s a big commitment, more so than for almost any other cancer. With this therapy — three days of the drug daunorubicin, which comes in a reddish color so distinctive that one of my patients, a former chemist, used it in his professional life as a dye for plastics, and seven days of
(More)…
Darren Hauck for The New York Times On the shores of Lake Michigan. When people choose to have their leukemia treated aggressively, it’s a big commitment, more so than for almost any other cancer. With this therapy — three days of the drug daunorubicin, which comes in a reddish color so distinctive that one of my patients, a former chemist, used it in his professional life as a dye for plastics, and seven days of
(More)…
NEW YORK–(BUSINESS WIRE)– Medivo Inc., a health monitoring platform that regularly connects doctors, consumers and clinical labs, today announced the launch of CML Monitor, a free mobile app for people living with chronic myelogenous (or myeloid) leukemia (CML). This new app simplifies daily life for people living with CML by providing them an innovative way to easily and accurately track BCR-ABL laboratory testing results and symptoms while delivering reports to their physicians for optimizing treatment.
(More)…
By Deena Beasley (Reuters) – An experimental drug from Gilead Sciences Inc shrank tumors in half of leukemia patients whose cancer had returned, according to an early-stage trial that represents a new foray into oncology by the world’s biggest seller of HIV medications. The pill, idelalisib, is part of a new class of medications designed to selectively block a type of protein known to promote tumor growth in patients with chronic lymphocytic leukemia (CLL) and
(More)…